Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
- Written by PR Newswire
--Further regulatory support for accelerated approval of Nefecon following NMPA's NDA acceptance with Breakthrough Therapy Designation—
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products...